Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023
Galmed Pharmaceuticals Ltd. - Ordinary Shares (GLMD)
Last galmed pharmaceuticals ltd. - ordinary shares earnings: 3/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
galmedpharma.investorroom.com
Company Research
Source: PR Newswire
TEL AVIV, Israel, April 4, 2024 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission (the "SEC"). The report is available on the SEC's website, at www.sec.gov and Galmed's Investor Relations website, at https://galmedpharma.investorroom.com/sec-filings.Shareholders can obtain copies of Galmed's Annual Report on Form 20-F, free of charge, by making a request within a reasonable period of time to Galmed's Investor Relations Department at investor.relations@galmedpharma.com.Galmed Pharmaceuticals Ltd.We are a clinical stage biopharmaceutical company focused on the development of Aramchol for liver and fibro-inflammatory diseases. We have focused almost exclusively on developing Aramchol for the treatment of NAS
Show less
Read more
Impact Snapshot
Event Time:
GLMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLMD alerts
High impacting Galmed Pharmaceuticals Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
GLMD
News
- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
GLMD
Sec Filings
- 4/4/24 - Form 20-F
- 3/19/24 - Form 6-K
- 3/15/24 - Form 6-K
- GLMD's page on the SEC website